NovaBridge Biosciences American Depositary Shares
NBP
29 hedge funds and large institutions have $7.41M invested in NovaBridge Biosciences American Depositary Shares in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
45% more call options, than puts
Call options by funds: $16K | Put options by funds: $11K
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.57% less ownership
Funds ownership: 6.4% → 4.83% (-1.6%)
27% less capital invested
Capital invested by funds: $10.1M → $7.41M (-$2.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$459K |
| 2 |
SG Americas Securities
New York
|
+$329K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$205K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$60.5K |
| 5 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$43.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.33M |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$119K |
| 3 |
Two Sigma Investments
New York
|
-$114K |
| 4 |
Two Sigma Advisers
New York
|
-$64.2K |
| 5 |
Millennium Management
New York
|
-$34.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
RhumbLine Advisers
Boston,
Massachusetts
| $297 | -$955 | -1,006 | -74% |
|
|
VWM
27
Vermillion Wealth Management
Rosemount,
Minnesota
| $165 | – | – | – |
|
28
Citigroup
New York
| $41 | – | – | – |
|
29
Osaic Holdings
Scottsdale,
Arizona
| $24 | +$28 | +30 | New |
|
|
CF
30
Cantor Fitzgerald
New York
| – | -$119K | -140,100 | Closed |
|
31
Legal & General Group
London,
United Kingdom
| – | -$1.01K | -1,191 | Closed |
|
32
Citadel Advisors
Miami,
Florida
| – | -$884 | -931 | Closed |
|
NBP Hedge Fund Activity: Q1 2025 in Review
29 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in NovaBridge Biosciences American Depositary Shares (NBP) for Q1 2025, worth a combined $7.41M — down 27% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NBP positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $459K. The largest seller was Morgan Stanley, cutting an estimated $3.33M.
- 29 institutional investors held NovaBridge Biosciences American Depositary Shares (NBP) as of Q1 2025, up from 28 in Q4 2024.
- Funds reported $7.41M of NovaBridge Biosciences American Depositary Shares stock for Q1 2025, down 27% quarter-over-quarter.
- 5 funds opened new NovaBridge Biosciences American Depositary Shares positions in Q1 2025 and 3 closed out, a net change of +2 holders.
- The largest NovaBridge Biosciences American Depositary Shares buyer in Q1 2025 was Stonepine Capital Management, an estimated $459K added.
- The largest NovaBridge Biosciences American Depositary Shares seller in Q1 2025 was Morgan Stanley, an estimated $3.33M sold.
Based on aggregated 13F filings for Q1 2025.